Spots Global Cancer Trial Database for Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

Official Title: Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy

Study ID: NCT00875004

Conditions

Anemia

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

epoetin beta

systemic chemotherapy

quality-of-life assessment

Study Description

Brief Summary: RATIONALE: Epoetin beta may cause the body to make more red blood cells and may prevent or reduce side effects in patients undergoing chemotherapy for solid tumors. PURPOSE: This clinical trial is studying how well epoetin beta works in patients undergoing chemotherapy for solid tumors.

Detailed Description: OBJECTIVES: Primary * Identify factors predictive of treatment failure in patients with solid tumors treated with epoetin beta while undergoing chemotherapy. Secondary * Evaluate the impact of achieving target hemoglobin levels (i.e., hemoglobin \> 11 g/dL) after 8 weeks of treatment with epoetin beta. * Evaluate changes in hemoglobin levels from baseline to after 8 weeks of treatment with epoetin beta. * Evaluate the tolerability of epoetin beta in these patients. * Evaluate the quality of life of these patients. OUTLINE: This is a multicenter study. Patients receive epoetin beta subcutaneously once a week for ≥ 8 weeks in the absence of disease progression or unacceptable toxicity. Patients complete a quality-of-life questionnaire (FACT-An) at baseline and after 8 weeks of treatment.